Category Archives: bapineuzumab

Bapineuzumab in Patients With Mild to Moderate Alzheimer’s Disease

This is a Phase III clinical trial and the study is currently recruiting participants.

This is a multi center, double-blind, placebo controlled, randomized, outpatient multiple dose study in male and female patients aged 50 to 89 years with mild to moderate AD. Approximately 200 study sites in the US and Canada will be involved. Patients will be randomized to receive either bapineuzumab or placebo. Each patient’s participation will last approximately 1.5 years.

You can get all the specifics on this Phase III clinical trial at Clinical

For a quick look at the locations participating in the study go to Locations

You can visit the Elan website to learn more about Bapineuzumab


Study Shows Alzheimer’s Drug Bapineuzumab effective in some patients

clipped from

Pharmaceutical partners Wyeth and Elan Corp. said Tuesday results from a highly anticipated midstage study of their experimental Alzheimer’s disease drug bapineuzumab show the treatment appears to be effective in some patients.

Bapineuzumab didn’t show a statistically significant difference compared with placebo in all patients, but the companies said it suggested a trend toward improving cognitive function.

Bapineuzumab is designed to work by attacking a substance in the brain called beta-amyloid. There is a growing scientific consensus that a buildup of beta-amyloid is responsible for Alzheimer’s.

blog it

%d bloggers like this: